Jennifer L McNeer1, Meenakshi Devidas2, Yunfeng Dai2, Andrew J Carroll3, Nyla A Heerema4, Julie M Gastier-Foster5, Samir B Kahwash5, Michael J Borowitz6, Brent L Wood7, Eric Larsen8, Kelly W Maloney9, Leonard Mattano10, Naomi J Winick11, Kirk R Schultz12, Stephen P Hunger13, William L Carroll14, Mignon L Loh15, Elizabeth A Raetz14. 1. 1 University of Chicago, Chicago, IL. 2. 2 University of Florida, Gainesville, FL. 3. 3 University of Alabama at Birmingham, Birmingham, AL. 4. 4 The Ohio State University, Columbus, OH. 5. 5 Nationwide Children's Hospital and The Ohio State University, Columbus, OH. 6. 6 Johns Hopkins Medical Institutions, Baltimore, MD. 7. 7 University of Washington, Seattle, WA. 8. 8 Maine Children's Cancer Program, Scarborough, ME. 9. 9 Children's Hospital Colorado, Aurora, CO. 10. 10 HARP Pharma Consulting, Mystic, CT. 11. 11 University of Texas Southwestern Medical Center, Dallas, TX. 12. 12 BC Children's Hospital and Research Institute, Vancouver, British Columbia, Canada. 13. 13 Children's Hospital of Philadelphia, Philadelphia, PA. 14. 14 New York University Langone Medical Center, New York, NY. 15. 15 University of California, San Francisco, San Francisco, CA.
Abstract
PURPOSE: Children and young adults with hypodiploid B-lymphoblastic leukemia (B-ALL) fare poorly and hematopoietic stem-cell transplantation (HSCT) is often pursued in first complete remission (CR1). We retrospectively reviewed the outcomes of children and young adults with hypodiploid B-ALL who were enrolled in recent Children's Oncology Group (COG) trials to evaluate the impact of HSCT on outcome. PATIENTS AND METHODS: Cytogenetic analyses and DNA index were performed at COG-approved laboratories, and hypodiploidy was defined as modal chromosome number less than 44 and/or DNA index less than 0.81. Minimal residual disease (MRD) was determined centrally using flow cytometry at two reference laboratories. Patients with hypodiploid ALL came off protocol therapy postinduction and we retrospectively collected details on their subsequent therapy and outcomes. Event-free survival (EFS) and overall survival (OS) were estimated for the cohort. RESULTS: Between 2003 and 2011, 8,522 patients with National Cancer Institute standard-risk and high-risk B-ALL were enrolled in COG AALL03B1 ( ClinicalTrials.gov identifier: NCT00482352). Hypodiploidy occurred in 1.5% of patients (n = 131), 98.3% of whom achieved CR after induction therapy. Five-year EFS and OS were 52.2% ± 4.9% and 58.9% ± 4.8%, respectively. Outcomes for patients undergoing CR1 HSCT were not significantly improved: 5-year EFS and OS were 57.4% ± 7.0% and 66.2% ± 6.6% compared with 47.8% ± 7.5% and 53.8% ± 7.6%, respectively ( P = .49 and .34, respectively) for those who did not undergo transplantation. Patients with MRD of 0.01% or greater at the end of induction had 5-year EFS and OS of 26.7% ± 9.3% and 29.3% ± 10.1%, respectively, and HSCT had no significant impact on outcomes. CONCLUSION: Children and young adults with hypodiploid B-ALL continue to fare poorly and do not seem to benefit from CR1 HSCT. This is especially true for patients with MRD of 0.01% or greater at the end of induction. New treatment strategies are urgently needed for these patients.
PURPOSE: Children and young adults with hypodiploid B-lymphoblastic leukemia (B-ALL) fare poorly and hematopoietic stem-cell transplantation (HSCT) is often pursued in first complete remission (CR1). We retrospectively reviewed the outcomes of children and young adults with hypodiploid B-ALL who were enrolled in recent Children's Oncology Group (COG) trials to evaluate the impact of HSCT on outcome. PATIENTS AND METHODS: Cytogenetic analyses and DNA index were performed at COG-approved laboratories, and hypodiploidy was defined as modal chromosome number less than 44 and/or DNA index less than 0.81. Minimal residual disease (MRD) was determined centrally using flow cytometry at two reference laboratories. Patients with hypodiploid ALL came off protocol therapy postinduction and we retrospectively collected details on their subsequent therapy and outcomes. Event-free survival (EFS) and overall survival (OS) were estimated for the cohort. RESULTS: Between 2003 and 2011, 8,522 patients with National Cancer Institute standard-risk and high-risk B-ALL were enrolled in COG AALL03B1 ( ClinicalTrials.gov identifier: NCT00482352). Hypodiploidy occurred in 1.5% of patients (n = 131), 98.3% of whom achieved CR after induction therapy. Five-year EFS and OS were 52.2% ± 4.9% and 58.9% ± 4.8%, respectively. Outcomes for patients undergoing CR1 HSCT were not significantly improved: 5-year EFS and OS were 57.4% ± 7.0% and 66.2% ± 6.6% compared with 47.8% ± 7.5% and 53.8% ± 7.6%, respectively ( P = .49 and .34, respectively) for those who did not undergo transplantation. Patients with MRD of 0.01% or greater at the end of induction had 5-year EFS and OS of 26.7% ± 9.3% and 29.3% ± 10.1%, respectively, and HSCT had no significant impact on outcomes. CONCLUSION: Children and young adults with hypodiploid B-ALL continue to fare poorly and do not seem to benefit from CR1 HSCT. This is especially true for patients with MRD of 0.01% or greater at the end of induction. New treatment strategies are urgently needed for these patients.
Authors: Charles G Mullighan; Sima Jeha; Deqing Pei; Debbie Payne-Turner; Elaine Coustan-Smith; Kathryn G Roberts; Esmé Waanders; John K Choi; Xiaotu Ma; Susana C Raimondi; Yiping Fan; Wenjian Yang; Guangchun Song; Jun J Yang; Hiroto Inaba; James R Downing; Wing H Leung; W Paul Bowman; Mary V Relling; William E Evans; Jinghui Zhang; Dario Campana; Ching-Hon Pui Journal: Blood Date: 2015-11-02 Impact factor: 22.113
Authors: Adriana Balduzzi; Maria Grazia Valsecchi; Cornelio Uderzo; Paola De Lorenzo; Thomas Klingebiel; Christina Peters; Jan Stary; Maria S Felice; Edina Magyarosy; Valentino Conter; Alfred Reiter; Chiara Messina; Helmut Gadner; Martin Schrappe Journal: Lancet Date: 2005 Aug 20-26 Impact factor: 79.321
Authors: Naomi Winick; Meenakshi Devidas; Si Chen; Kelly Maloney; Eric Larsen; Leonard Mattano; Michael J Borowitz; Andrew Carroll; Julie M Gastier-Foster; Nyla A Heerema; Cheryl Willman; Brent Wood; Mignon L Loh; Elizabeth Raetz; Stephen P Hunger; William L Carroll Journal: J Clin Oncol Date: 2017-05-23 Impact factor: 44.544
Authors: Prakash Satwani; Harland Sather; Fevzi Ozkaynak; Nyla A Heerema; Kirk R Schultz; Jean Sanders; John Kersey; Virginia Davenport; Michael Trigg; Mitchell S Cairo Journal: Biol Blood Marrow Transplant Date: 2007-02 Impact factor: 5.742
Authors: Susana C Raimondi; Yinmei Zhou; Susan Mathew; Sheila A Shurtleff; John T Sandlund; Gaston K Rivera; Frederick G Behm; Ching-Hon Pui Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: C H Pui; D L Williams; S C Raimondi; G K Rivera; A T Look; R K Dodge; S L George; F G Behm; W M Crist; S B Murphy Journal: Blood Date: 1987-07 Impact factor: 22.113
Authors: Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Donald A Berry; Shouhao Zhou; Howard Higley; Lata Mukundan; Shuangshuang Fu; Gregory H Reaman; Brent L Wood; Gary J Kelloff; J Milburn Jessup; Jerald P Radich Journal: JAMA Oncol Date: 2017-07-13 Impact factor: 31.777
Authors: Jeremy M Schraw; Jacob J Junco; Austin L Brown; Michael E Scheurer; Karen R Rabin; Philip J Lupo Journal: EBioMedicine Date: 2019-10-17 Impact factor: 8.143
Authors: Christina Peters; Jean-Hugues Dalle; Franco Locatelli; Ulrike Poetschger; Petr Sedlacek; Jochen Buechner; Peter J Shaw; Raquel Staciuk; Marianne Ifversen; Herbert Pichler; Kim Vettenranta; Peter Svec; Olga Aleinikova; Jerry Stein; Tayfun Güngör; Jacek Toporski; Tony H Truong; Cristina Diaz-de-Heredia; Marc Bierings; Hany Ariffin; Mohammed Essa; Birgit Burkhardt; Kirk Schultz; Roland Meisel; Arjan Lankester; Marc Ansari; Martin Schrappe; Arend von Stackelberg; Adriana Balduzzi; Selim Corbacioglu; Peter Bader Journal: J Clin Oncol Date: 2020-12-17 Impact factor: 44.544
Authors: Oscar Molina; Alex Bataller; Namitha Thampi; Jordi Ribera; Isabel Granada; Pablo Velasco; José Luis Fuster; Pablo Menéndez Journal: Cancers (Basel) Date: 2021-12-22 Impact factor: 6.639